ホーム>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>Indibulin

Indibulin (Synonyms: D-24851, ZIO 301)

カタログ番号GC36308

インジブリン (ZIO 301) は、経口で適用可能なチューブリン アセンブリの阻害剤であり、最小限の神経毒性で強力な抗がん作用を示します。

Products are for research use only. Not for human use. We do not sell to patients.

Indibulin 化学構造

Cas No.: 204205-90-3

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$112.00
在庫あり
5mg
$102.00
在庫あり
10mg
$148.00
在庫あり
50mg
$538.00
在庫あり
100mg
$946.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Indibulin (ZIO 301) , an orally applicable inhibitor of tubulin assembly, shows potent anticancer activity with a minimal neurotoxicity. Indibulin reduces inter-kinetochoric tension, produces aberrant spindles, activates mitotic checkpoint proteins Mad2 and BubR1, and induces mitotic arrest and apoptosis[1]. Tubulin[1]

Indibulin (300-2100 nM; 48 hours) inhibits the proliferation of MCF-7 cells with an IC50 of 150 nM[1]. Indibulin (300, 600 nM; 48 hours) blockes the cells in the G2/M phase indicating that indibulin blockes the progression of the cell cycle at mitosis[1]. Indibulin (150-600 nM; 24 hours) induces apoptosis in MCF-7 cells[1]. Indibulin (150-600 nM; 48 hours) with 300 and 600 nM generates cleaved fragments of PARP protein the treatment of MCF-7 cells[1]. Cell Proliferation Assay[1] Cell Line: MCF-7 cells

[1]. Kapoor S, et al. Indibulin dampens microtubule dynamics and produces synergistic antiproliferative effect with vinblastine in MCF-7 cells: Implications in cancer chemotherapy. Sci Rep. 2018 Aug 17;8(1):12363.

レビュー

Review for Indibulin

Average Rating: 5 ★★★★★ (Based on Reviews and 33 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Indibulin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.